Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
Phase III Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib E7080/MK-7902 in Combination with Pembrolizumab MK-3475 Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma LEAP-002
Single Person IND for the Use of TK216 in a patient with metastatic Ewing sarcoma
Study Type: Treatment
Phase: N/A
NCTID: NCT00000000
Principal Investigator:
Benjamin Powers
A Randomized Open-Label Phase II/III Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer Duravelo-2
A Phase I/Ib Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction GEJ Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumor Have Claudin CLDN 18.2 Expression
Study Type: Treatment
Phase: I
NCTID: NCT05365581
Principal Investigator:
Anup Kasi
Immune Checkpoint Inhibitor Toxicity I-CHECKIT: A Prospective Observational Study
Study Type: Supportive Care
Phase: IV
NCTID: NCT04871542
Principal Investigator:
Saqib Abbasi
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician's Choice of Endocrine Therapy Plus Everolimus in Patients with Estrogen Receptor-Positive, HER-Negative, Locally Advanced or Metastatic Breast Cancer
A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
A Phase II Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway?Mutant Acute Lymphoblastic Leukemia
Study Type: Treatment
Phase: II
NCTID: NCT02723994
Principal Investigator:
Kevin Ginn